中国生物制药(01177):TQB3205“PAN-KRAS抑制剂”临床试验申请获FDA批准

智通财经
Apr 09

智通财经APP讯,中国生物制药(01177)发布公告,集团附属公司正大天晴药业集团股份有限公司(正大天晴)自主研发的创新药TQB3205“Pan-KRAS抑制剂”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批准,用于晚期恶性肿瘤。

TQB3205胶囊是一款口服Pan-KRAS抑制剂,可与多种KRAS突变蛋白实现高亲和力结合,将KRAS 蛋白锁定于失活状态,从而阻断下游信号通路(如MAPK通路及PI3K-AKT通路),最终有效抑制多种 KRAS突变肿瘤细胞的增殖,从靶点层面精准发挥抗肿瘤效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10